No Data
No Data
Guangzhou Wondfo Biotech (300482.SZ): The company's malaria detection products have passed the WHO's PQ certification.
On July 31st, Gelonhui reported that Guangzhou Wondfo Biotech (300482.SZ) has recently received a letter of confirmation from the World Health Organization (WHO) for pre-qualification (PQ) of in vitro diagnostic products. The company's malaria detection products have been pre-qualified by the World Health Organization and have been included in the recommended procurement list for in vitro diagnostic products. The product name is the Wondfo Malaria P.f (HRP2/pLDH) Test. This detection product is used for qualitative detection of Plasmodium falciparum-specific histidine-rich protein-2 (P.fHRP2) in human fingertip whole blood and venous whole blood.
Guangzhou Wondfo BiotechLtd (SZSE:300482) Seems To Use Debt Quite Sensibly
Guangzhou Wondfo Biotech (300482.SZ) granted 13.39 million restricted stocks to 236 incentive recipients.
On July 24th, Gelunhui reported that Guangzhou Wondfo Biotech (300482.SZ) announced that the first grant condition of restricted stocks, as stipulated in the company's "2024 Restricted Stock Incentive Plan" (draft), has been achieved. It is determined that July 24, 2024 will be the date of the first grant, and 13.39 million restricted stocks will be granted to 236 incentive objects who meet the grant conditions at a grant price of 12.82 yuan per share.
Retail Investors Who Hold 40% of Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) Gained 6.1%, Insiders Profited as Well
Guangzhou Wondfo Biotech (300482.SZ): Currently focusing on toxicology business in the US market.
Guangzhou Wondfo Biotech (300482.SZ) stated on the investor interaction platform on July 10 that the company's business in the USA is currently mainly focused on drug testing. The company has been deeply cultivating the US market for many years, continuously strengthening the construction of the US drug testing market, and is committed to providing the most comprehensive drug testing solutions in the industry. At the same time, the company is also constantly promoting the import of respiratory testing products and promoting the continuous and stable growth of business in the US market.
Guangzhou Wondfo Biotech (300482.SZ): Plans to launch a 2024 restricted stock incentive program for 14.16 million shares.
On July 5th, Gelon Hui reported that Guangzhou Wondfo Biotech (300482.SZ) announced its 2024 restricted stocks incentive plan (draft). The plan intends to grant 14.16 million restricted stocks to the incentive recipients, accounting for approximately 3.00% of the company's total stock of 471.771537 million shares at the time of the announcement of this draft incentive plan. Of these, 13.39 million restricted stocks are granted for the first time, accounting for approximately 2.84% of the company's total stock of 471.771537 million shares at the time of the announcement of this draft incentive plan, representing 94.56% of the total number of restricted stocks to be granted under this incentive plan. Some restricted stocks are reserved.
No Data